cilostazol has been researched along with Angiospasm, Intracranial in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol, a phosphodiesterase III inhibitor, appears to be a promising agent for preventing cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage." | 9.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 9.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| "Several clinical studies have indicated the efficacy of cilostazol, a selective inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH)." | 9.22 | Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Asano, K; Hasegawa, S; Ito, K; Matsuda, N; Naraoka, M; Ohkuma, H; Shimamura, N; Takemura, A, 2016) |
| "In order to prevent cerebral vasospasm (VS) following aneurysmal subarachnoid hemorrhage (SAH), we introduced combined enteral nutrition (EN) and parenteral nutrition (PN) with oral cilostazol administration to the postoperative patient after SAH and investigated the effect on VS." | 9.20 | Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage. ( Chiba, Y; Fujimoto, Y; Hori, T; Ishii, T; Kimura, H; Kohmura, E; Maeyama, M; Okamura, Y; Shigeru, M; Shiomi, R; Yamamoto, Y, 2015) |
| " Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge." | 9.15 | Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. ( Inoue, T; Mannoji, H; Nakamura, T; Nishimura, H; Ohta, M; Sayama, T; Suzuki, S; Takeshita, I, 2011) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 9.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects." | 8.98 | Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. ( Desai, A; Ibrahim, M; Mohamed, W; Palla, M; Saber, H; Seraji-Bozorgzad, N, 2018) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 7.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "Selective inhibition of phosphodiesterase type III (PDE III) may be involved in the pathophysiology of vasospasm and a PDE III inhibitor, cilostazol, is thus expected to attenuate vasospasm after subarachnoid hemorrhage (SAH)." | 7.75 | Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. ( Mizutani, A; Namba, H; Nishizawa, S; Yamaguchi-Okada, M, 2009) |
| "The purpose of this study was to use black blood magnetic resonance imaging (BB-MRI) to assess delayed cerebral vasospasm (DCV) after subarachnoid hemorrhage (SAH) in rats, and evaluate whether delayed treatment with the anti-platelet agent cilostazol was effective on DCV." | 7.74 | Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. ( Fukunaga, M; Ishikawa, M; Ito, H; Miyakoda, G; Suzuki, H; Taki, W; Yabuuchi, Y, 2008) |
| "Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) remains an important problem with a complex pathophysiology." | 7.01 | Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia. ( Inoue, T; Ishihara, H; Kawano, A; Kawano, R; Nomura, S; Oka, F; Sadahiro, H; Sugimoto, K; Suzuki, M, 2021) |
| " Furthermore, we examined whether clinical outcomes were associated with the dosage of cilostazol (300 mg/day vs." | 6.82 | Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis. ( Awil, MA; Chen, X; Feng, Y; He, J; Hou, D; Liu, J; Tian, Y; Wang, C; Wang, Y, 2022) |
| "Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH) is a major cause of subsequent morbidity and mortality." | 6.78 | Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. ( Fukamachi, A; Fukasawa, I; Furuya, K; Horikoshi, T; Kanemaru, K; Kinouchi, H; Kobayashi, C; Koizumi, H; Kuroda, K; Nakano, S; Nishiyama, Y; Ohashi, Y; Senbokuya, N; Shimizu, T; Takahashi, T; Takeuchi, N; Uchida, M; Yagi, S; Yoshioka, H, 2013) |
| "Many drugs have been tried to mitigate cerebral vasospasm and delayed cerebral ischemia." | 6.72 | Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. ( Bohara, S; Garg, K; Kasliwal, M; Singh Rajpal, PM, 2021) |
| "Cilostazol, a phosphodiesterase III inhibitor, appears to be a promising agent for preventing cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage." | 5.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "Cilostazol is a specific inhibitor of cAMP(cyclic adenosine monophosphate)phosphodiesterase, and is used for treating ischemic symptoms of peripheral vascular disease." | 5.39 | [The efficiency of cilostazol for cerebral vasospasm following subarachnoid hemorrhage]. ( Hara, K; Kamiyama, K; Mikamoto, M; Murahashi, T; Nakagaki, Y; Nakamura, H; Ozaki, M, 2013) |
| "We investigated these effects on cerebral vasospasm after rat SAH." | 5.36 | Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. ( Fujinaka, T; Nishino, A; Umegaki, M; Yoshimine, T, 2010) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 5.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 5.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| "Nimodipine and cilostazol are likely the most effective treatments in preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage." | 5.22 | Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. ( Ahmadvand, S; Amin-Hanjani, S; Dayyani, M; Grotta, JC; Guyatt, GH; Sadeghirad, B; Wang, Y; Zabihyan, S, 2022) |
| "Several clinical studies have indicated the efficacy of cilostazol, a selective inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH)." | 5.22 | Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Asano, K; Hasegawa, S; Ito, K; Matsuda, N; Naraoka, M; Ohkuma, H; Shimamura, N; Takemura, A, 2016) |
| "In order to prevent cerebral vasospasm (VS) following aneurysmal subarachnoid hemorrhage (SAH), we introduced combined enteral nutrition (EN) and parenteral nutrition (PN) with oral cilostazol administration to the postoperative patient after SAH and investigated the effect on VS." | 5.20 | Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage. ( Chiba, Y; Fujimoto, Y; Hori, T; Ishii, T; Kimura, H; Kohmura, E; Maeyama, M; Okamura, Y; Shigeru, M; Shiomi, R; Yamamoto, Y, 2015) |
| " Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge." | 5.15 | Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. ( Inoue, T; Mannoji, H; Nakamura, T; Nishimura, H; Ohta, M; Sayama, T; Suzuki, S; Takeshita, I, 2011) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 5.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects." | 4.98 | Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. ( Desai, A; Ibrahim, M; Mohamed, W; Palla, M; Saber, H; Seraji-Bozorgzad, N, 2018) |
| "Selective inhibition of phosphodiesterase type III (PDE III) may be involved in the pathophysiology of vasospasm and a PDE III inhibitor, cilostazol, is thus expected to attenuate vasospasm after subarachnoid hemorrhage (SAH)." | 3.75 | Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. ( Mizutani, A; Namba, H; Nishizawa, S; Yamaguchi-Okada, M, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 3.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "The purpose of this study was to use black blood magnetic resonance imaging (BB-MRI) to assess delayed cerebral vasospasm (DCV) after subarachnoid hemorrhage (SAH) in rats, and evaluate whether delayed treatment with the anti-platelet agent cilostazol was effective on DCV." | 3.74 | Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. ( Fukunaga, M; Ishikawa, M; Ito, H; Miyakoda, G; Suzuki, H; Taki, W; Yabuuchi, Y, 2008) |
| "Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) remains an important problem with a complex pathophysiology." | 3.01 | Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia. ( Inoue, T; Ishihara, H; Kawano, A; Kawano, R; Nomura, S; Oka, F; Sadahiro, H; Sugimoto, K; Suzuki, M, 2021) |
| " Furthermore, we examined whether clinical outcomes were associated with the dosage of cilostazol (300 mg/day vs." | 2.82 | Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis. ( Awil, MA; Chen, X; Feng, Y; He, J; Hou, D; Liu, J; Tian, Y; Wang, C; Wang, Y, 2022) |
| "Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH) is a major cause of subsequent morbidity and mortality." | 2.78 | Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. ( Fukamachi, A; Fukasawa, I; Furuya, K; Horikoshi, T; Kanemaru, K; Kinouchi, H; Kobayashi, C; Koizumi, H; Kuroda, K; Nakano, S; Nishiyama, Y; Ohashi, Y; Senbokuya, N; Shimizu, T; Takahashi, T; Takeuchi, N; Uchida, M; Yagi, S; Yoshioka, H, 2013) |
| "Cilostazol was found to be the second-best treatment in improving favorable outcomes (OR, 3." | 2.72 | Effects of Various Therapeutic Agents on Vasospasm and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage-Results of a Network Meta-Analysis. ( Chandra, PS; Gaonkar, VB; Garg, K; Kale, SS; Mishra, S; Singh, M; Singh, PM; Suri, A, 2021) |
| "Many drugs have been tried to mitigate cerebral vasospasm and delayed cerebral ischemia." | 2.72 | Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. ( Bohara, S; Garg, K; Kasliwal, M; Singh Rajpal, PM, 2021) |
| "• 33." | 2.55 | Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis. ( Ben Hassen, W; Boulouis, G; Bresson, D; Labeyrie, MA; Lukaszewicz, AC; Meder, JF; Naggara, O; Oppenheim, C; Raymond, J; Rodriguez-Régent, C; Trystram, D, 2017) |
| "If both treatments are available for ruptured aneurysms, clinicians should choose EC on the basis of its ability to prevent DIND." | 1.72 | Comparison of Symptomatic Vasospasm after Surgical Clipping and Endovascular Coiling. ( Adachi, H; Akiyama, T; Asakura, K; Fukuda, T; Fukui, N; Fukumitsu, R; Horii, R; Imamura, H; Kajiura, S; Omura, Y; Sakai, N; Sasaki, N; Shigeyasu, M; Sunohara, T; Tani, S, 2022) |
| "Cilostazol is a specific inhibitor of cAMP(cyclic adenosine monophosphate)phosphodiesterase, and is used for treating ischemic symptoms of peripheral vascular disease." | 1.39 | [The efficiency of cilostazol for cerebral vasospasm following subarachnoid hemorrhage]. ( Hara, K; Kamiyama, K; Mikamoto, M; Murahashi, T; Nakagaki, Y; Nakamura, H; Ozaki, M, 2013) |
| "We investigated these effects on cerebral vasospasm after rat SAH." | 1.36 | Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. ( Fujinaka, T; Nishino, A; Umegaki, M; Yoshimine, T, 2010) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 1.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Kawano, A | 1 |
| Sugimoto, K | 1 |
| Nomura, S | 1 |
| Inoue, T | 2 |
| Kawano, R | 1 |
| Oka, F | 1 |
| Sadahiro, H | 1 |
| Ishihara, H | 1 |
| Suzuki, M | 1 |
| Li, L | 1 |
| Fu, X | 1 |
| Qiu, H | 1 |
| Shi, P | 1 |
| Liu, J | 1 |
| He, J | 1 |
| Chen, X | 1 |
| Feng, Y | 1 |
| Wang, C | 1 |
| Awil, MA | 1 |
| Wang, Y | 2 |
| Tian, Y | 1 |
| Hou, D | 1 |
| Dayyani, M | 1 |
| Sadeghirad, B | 1 |
| Grotta, JC | 1 |
| Zabihyan, S | 1 |
| Ahmadvand, S | 1 |
| Guyatt, GH | 1 |
| Amin-Hanjani, S | 1 |
| Imamura, H | 1 |
| Tani, S | 1 |
| Adachi, H | 1 |
| Fukumitsu, R | 1 |
| Sunohara, T | 1 |
| Fukui, N | 1 |
| Omura, Y | 1 |
| Sasaki, N | 1 |
| Akiyama, T | 1 |
| Fukuda, T | 1 |
| Kajiura, S | 1 |
| Shigeyasu, M | 1 |
| Asakura, K | 1 |
| Horii, R | 1 |
| Sakai, N | 1 |
| Qureshi, AI | 3 |
| Akhtar, IN | 3 |
| Ma, X | 3 |
| Lodhi, A | 3 |
| Bhatti, I | 3 |
| Beall, J | 3 |
| Broderick, JP | 3 |
| Cassarly, CN | 3 |
| Martin, RH | 3 |
| Sharma, R | 3 |
| Thakkar, M | 3 |
| Suarez, JI | 3 |
| Bohara, S | 1 |
| Garg, K | 2 |
| Singh Rajpal, PM | 1 |
| Kasliwal, M | 1 |
| Mishra, S | 1 |
| Gaonkar, VB | 1 |
| Singh, PM | 1 |
| Singh, M | 1 |
| Suri, A | 1 |
| Chandra, PS | 1 |
| Kale, SS | 1 |
| Saber, H | 1 |
| Desai, A | 1 |
| Palla, M | 1 |
| Mohamed, W | 1 |
| Seraji-Bozorgzad, N | 1 |
| Ibrahim, M | 1 |
| Shan, T | 1 |
| Zhang, T | 1 |
| Qian, W | 1 |
| Ma, L | 1 |
| Li, H | 1 |
| You, C | 1 |
| Xie, X | 1 |
| Murahashi, T | 1 |
| Kamiyama, K | 1 |
| Hara, K | 1 |
| Ozaki, M | 1 |
| Mikamoto, M | 1 |
| Nakagaki, Y | 2 |
| Nakamura, H | 1 |
| Shimamura, N | 2 |
| Ohkuma, H | 2 |
| Kimura, H | 1 |
| Okamura, Y | 1 |
| Chiba, Y | 1 |
| Shigeru, M | 1 |
| Ishii, T | 1 |
| Hori, T | 1 |
| Shiomi, R | 1 |
| Yamamoto, Y | 1 |
| Fujimoto, Y | 1 |
| Maeyama, M | 1 |
| Kohmura, E | 1 |
| Matsuda, N | 1 |
| Naraoka, M | 1 |
| Ito, K | 1 |
| Asano, K | 1 |
| Hasegawa, S | 1 |
| Takemura, A | 1 |
| Boulouis, G | 1 |
| Labeyrie, MA | 1 |
| Raymond, J | 1 |
| Rodriguez-Régent, C | 1 |
| Lukaszewicz, AC | 1 |
| Bresson, D | 1 |
| Ben Hassen, W | 1 |
| Trystram, D | 1 |
| Meder, JF | 1 |
| Oppenheim, C | 1 |
| Naggara, O | 1 |
| Ito, H | 1 |
| Fukunaga, M | 1 |
| Suzuki, H | 1 |
| Miyakoda, G | 1 |
| Ishikawa, M | 1 |
| Yabuuchi, Y | 1 |
| Taki, W | 1 |
| Yamaguchi-Okada, M | 1 |
| Nishizawa, S | 1 |
| Mizutani, A | 1 |
| Namba, H | 1 |
| Yoshimoto, T | 1 |
| Shirasaka, T | 1 |
| Fujimoto, S | 1 |
| Yoshidumi, T | 1 |
| Yamauchi, T | 1 |
| Tokuda, K | 1 |
| Kaneko, S | 1 |
| Kashiwaba, T | 1 |
| Bilginer, B | 1 |
| Onal, MB | 1 |
| Narin, F | 1 |
| Soylemezoglu, F | 1 |
| Ziyal, IM | 1 |
| Ozgen, T | 1 |
| Nishino, A | 1 |
| Umegaki, M | 1 |
| Fujinaka, T | 1 |
| Yoshimine, T | 1 |
| Suzuki, S | 1 |
| Sayama, T | 1 |
| Nakamura, T | 1 |
| Nishimura, H | 1 |
| Ohta, M | 1 |
| Mannoji, H | 1 |
| Takeshita, I | 1 |
| Senbokuya, N | 1 |
| Kinouchi, H | 1 |
| Kanemaru, K | 1 |
| Ohashi, Y | 1 |
| Fukamachi, A | 1 |
| Yagi, S | 1 |
| Shimizu, T | 1 |
| Furuya, K | 1 |
| Uchida, M | 1 |
| Takeuchi, N | 1 |
| Nakano, S | 1 |
| Koizumi, H | 1 |
| Kobayashi, C | 1 |
| Fukasawa, I | 1 |
| Takahashi, T | 1 |
| Kuroda, K | 1 |
| Nishiyama, Y | 1 |
| Yoshioka, H | 1 |
| Horikoshi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for cilostazol and Angiospasm, Intracranial
| Article | Year |
|---|---|
Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Treatment Outcome; | 2022 |
Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis.
Topics: Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Treatment Outcome; Vasospasm, Intr | 2022 |
Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Topics: Adult; Brain Ischemia; Cilostazol; Humans; Magnesium; Morbidity; Network Meta-Analysis; Nicardipine; | 2022 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Role of Cilostazol in Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage-A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Topics: Cilostazol; Humans; Phosphodiesterase 3 Inhibitors; Randomized Controlled Trials as Topic; Subarachn | 2021 |
Effects of Various Therapeutic Agents on Vasospasm and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage-Results of a Network Meta-Analysis.
Topics: Cilostazol; Delayed-Action Preparations; Humans; Network Meta-Analysis; Nicardipine; Randomized Cont | 2021 |
Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Topics: Aged; Brain Ischemia; Chi-Square Distribution; Cilostazol; Female; Humans; Male; Middle Aged; Odds R | 2018 |
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Brain Ischemia; Cardiovascular Agents; Cerebral Infarction; Cilostazol; Humans; Intracranial Aneurys | 2020 |
Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Animals; Cilostazol; Humans; Inflammation; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phenot | 2014 |
Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis.
Topics: Cilostazol; Endovascular Procedures; Humans; Prognosis; Randomized Controlled Trials as Topic; Subar | 2017 |
5 trials available for cilostazol and Angiospasm, Intracranial
| Article | Year |
|---|---|
Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia.
Topics: Brain Ischemia; Cilostazol; Humans; Microcirculation; Prospective Studies; Subarachnoid Hemorrhage; | 2021 |
Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage.
Topics: Aged; Cilostazol; Combined Modality Therapy; Enteral Nutrition; Female; Humans; Male; Middle Aged; N | 2015 |
Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Cerebral Angiography; Cerebral Art | 2016 |
Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report.
Topics: Aged; Cerebral Infarction; Cilostazol; Female; Humans; Incidence; Male; Middle Aged; Phosphodiestera | 2011 |
Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial.
Topics: Aged; Cilostazol; Female; Humans; Male; Middle Aged; Phosphodiesterase 3 Inhibitors; Prospective Stu | 2013 |
7 other studies available for cilostazol and Angiospasm, Intracranial
| Article | Year |
|---|---|
Comparison of Symptomatic Vasospasm after Surgical Clipping and Endovascular Coiling.
Topics: Aneurysm, Ruptured; Cilostazol; Humans; Intracranial Aneurysm; Retrospective Studies; Subarachnoid H | 2022 |
[The efficiency of cilostazol for cerebral vasospasm following subarachnoid hemorrhage].
Topics: Adult; Aged; Aged, 80 and over; Cilostazol; Female; Humans; Incidence; Male; Middle Aged; Subarachno | 2013 |
Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging.
Topics: Animals; Cilostazol; Magnetic Resonance Imaging; Male; Rats; Rats, Sprague-Dawley; Subarachnoid Hemo | 2008 |
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Topics: Administration, Oral; Animals; Basilar Artery; Cerebral Angiography; Cilostazol; Cyclic Nucleotide P | 2009 |
Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebral Infarction; Cilostazol; Disability | 2009 |
The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model.
Topics: Animals; Basilar Artery; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; Injections, | 2009 |
Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.
Topics: Animals; Cilostazol; Disease Models, Animal; Male; Neuroprotective Agents; Random Allocation; Rats; | 2010 |